Physician profile
Naima Anwer
NPI 1164653085
$6,761.39
in general payments reported to CMS, 2019-2025
37 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $623 · 2021: $773 · 2022: $776 · 2023: $983 · 2024: $1,629 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,178.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,768.46 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,123.43 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $721.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $380.59 | 2019-2025 | Zepbound, Mounjaro, Trulicity |
| Pfizer INC. | $335.03 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $259.26 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $230.38 | 2019-2025 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $196.58 | 2024-2025 | Voquezna |
| Amgen INC. | $155.82 | 2020-2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.65 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $130.23 | 2023 | Quviviq |
| Amarin Pharma, INC. | $129.92 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $127.91 | 2020-2025 | Contrave, Onzetra Xsail |
| Astellas Pharma US INC | $125.56 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $113.05 | 2023-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naima Anwer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.